Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Gao Yan, Xue-Ping Li, Xiaoxiao Wang, Xiaoyu Hong, Bing Bai, Xuanye Zhang, Jialing Zhuang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2024-207630

Published: 2024

Journal Articles

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Gao Yan, Xue-Ping Li, Bing Bai, Xiaoxiao Wang, Xuanye Zhang, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2024-205253

Published: 2024

Journal Articles

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Blood (2024) 144 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2024-201598

Published: 2024

Journal Articles

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Yanxia He, Yan Gao, Xiaoxiao Wang, Bing Bai, Zhiming Li, Haixia He, Liqin Ping, Cheng Huang, Haoqing Chen, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6218.

https://doi.org/10.1182/blood-2023-186496

Published: 2023

Journal Articles

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Gao Yan, Liling Zhang, Wenyu Li, Xu Wei, Ru Feng, Xue-Ping Li, Yu Chen, Huijing Wu, Xiaoxiao Wang, Bing Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 1689.

https://doi.org/10.1182/blood-2023-186252

Published: 2023

Journal Articles

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yu-Hua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2023-186099

Published: 2023

Journal Articles

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Liqin Ping, Xiaoxiao Wang, Yan Gao, Bing Bai, He Huang, Linbo Cai, Hui Zhou, Changguo Shan, Zhiming Li, Mingyao Lai, Haixia He, Cheng Huang, Haoqing Chen, Ru Feng, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2023-185212

Published: 2023

Journal Articles

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Gao Yan, Qingqing Cai, Zhiming Li, Xiaoxiao Wang, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2023-181619

Published: 2023

Journal Articles

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Gao Yan, Cheng Huang, Xue-Ping Li, Xiaoxiao Wang, Bing Bai, Yanxia He, Liqin Ping, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 9393–9394.

https://doi.org/10.1182/blood-2022-165874

Published: 2022

Journal Articles

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

Gao Yan, Xiaoxiao Wang, Bing Bai, Xue-Ping Li, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 3737–3738.

https://doi.org/10.1182/blood-2022-166936

Published: 2022

Journal Articles

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Yan Gao, Shanshan Yu, Xiaoyu Hong, Mingyao Lai, Chao Yang, Yang Shao, Linbo Cai, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 6606–6607.

https://doi.org/10.1182/blood-2022-169608

Published: 2022

Journal Articles

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Yan Gao, Shanshan Yu, Bing Bai, Qiuxiang Ou, Liuqing Zhu, He Huang, Hui Zhou, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2021) 138 (Supplement 1): 2481.

https://doi.org/10.1182/blood-2021-150658

Published: 2021

Journal Articles

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2021-152018

Published: 2021

Journal Articles

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Gao Yan, Yujing Zhang, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang

Blood (2021) 138 (Supplement 1): 137.

https://doi.org/10.1182/blood-2021-147169

Published: 2021

Journal Articles

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Xiaoxiao Wang, Yan Gao, MD PhD, Changguo Shan, Mingyao Lai, Haixia He, Bing Bai, Li-qin Ping, Qixiang Rong, Ruyu Ai, Lei Wen, Zhaoming Zhou, Ruoying Yu, Qiuxiang Ou, Xue Wu, Xiaoxia Wang, Yang Shao, Linbo Cai, Hui-qiang Huang

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-134804

Published: 2020

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Yan Gao, MD PhD, Huiqiang Huang, MDPhD, Xiaoxiao Wang, Bing Bai, Liling Zhang, MD PhD, Yin Xiao, Xinxiu Liu, Wenyu Li, PhD, Wei Xu, MD PhD, Ru Feng, Yu Chen, Huijing Wu, Jibin Li, Xue Wu

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-134665

Published: 2020

Journal Articles

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141752

Published: 2020

Journal Articles

Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Yan Gao, Huiqiang Huang, MD, Yujing Zhang, Hang Su, Xiaoxiao Wang, Bing Bai, Yunhong Huang, Yuhuan Gao, Liping Su, MD, Xiaoxia Chu, Wenyu Li, Junyi Zhang, Qiaohua Zhang, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang, MD PhD

Blood (2016) 128 (22): 1819.

https://doi.org/10.1182/blood.V128.22.1819.1819

Published: 2016

Journal Articles

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Wei Zhao, Zheng Yan, Wenqi Jiang, MD PhD, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 1521.

https://doi.org/10.1182/blood.V126.23.1521.1521

Published: 2015

Journal Articles

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Zheng Yan, Wenqi Jiang, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 3936.

https://doi.org/10.1182/blood.V126.23.3936.3936

Published: 2015

NARROW

Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission

Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Preliminary Results of a Phase II Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Pegaspargase Plus Gemcitabine, Oxaliplatin(P-Gemox) and Thalidomide Versus Aspermetdex Regimen for the Patients with Early or Advanced/Relapsed Extranodal Natural Killer/T Cell Lymphoma: Interim Analysis of a Prospective,Multicenter, Randomized, Phase III Non-Inferiority Clinical Trial

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only